[go: up one dir, main page]

FR3059429B1 - PROCESS FOR IMPUTING A NON-NEGATIVE RESPONSE OBTAINED IN A REVERSE MUTATION TEST ON BACTERIA, CARRIED OUT FROM A PHARMACEUTICAL, COSMETIC OR NUTRITIONAL PREPARATION, AT LEAST ONE CONSTITUENT IDENTIFIED AS MUTAGEN IN VITRO - Google Patents

PROCESS FOR IMPUTING A NON-NEGATIVE RESPONSE OBTAINED IN A REVERSE MUTATION TEST ON BACTERIA, CARRIED OUT FROM A PHARMACEUTICAL, COSMETIC OR NUTRITIONAL PREPARATION, AT LEAST ONE CONSTITUENT IDENTIFIED AS MUTAGEN IN VITRO Download PDF

Info

Publication number
FR3059429B1
FR3059429B1 FR1661745A FR1661745A FR3059429B1 FR 3059429 B1 FR3059429 B1 FR 3059429B1 FR 1661745 A FR1661745 A FR 1661745A FR 1661745 A FR1661745 A FR 1661745A FR 3059429 B1 FR3059429 B1 FR 3059429B1
Authority
FR
France
Prior art keywords
bacteria
imputing
mutagen
cosmetic
vitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1661745A
Other languages
French (fr)
Other versions
FR3059429A1 (en
Inventor
Cecile Miette
Morcq Karine Ancolio
Didier Guedon
Philippe Abbe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Arkopharma SA
Original Assignee
Laboratoires Arkopharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Arkopharma SA filed Critical Laboratoires Arkopharma SA
Priority to FR1661745A priority Critical patent/FR3059429B1/en
Publication of FR3059429A1 publication Critical patent/FR3059429A1/en
Application granted granted Critical
Publication of FR3059429B1 publication Critical patent/FR3059429B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Procédé de préparation et de fractionnement d'une solution d'essai adaptée pour subir un test de mutation réverse sur bactéries en présence et/ou en absence d'activation métabolique exogène, et procédé permettant d'imputer une réponse non négative obtenue lors d'un premier test de mutation réverse sur bactéries.Process for preparing and fractionating a test solution suitable for undergoing a reverse mutation test on bacteria in the presence and / or absence of exogenous metabolic activation, and process for imputing a non-negative response obtained during a first reverse mutation test on bacteria.

FR1661745A 2016-11-30 2016-11-30 PROCESS FOR IMPUTING A NON-NEGATIVE RESPONSE OBTAINED IN A REVERSE MUTATION TEST ON BACTERIA, CARRIED OUT FROM A PHARMACEUTICAL, COSMETIC OR NUTRITIONAL PREPARATION, AT LEAST ONE CONSTITUENT IDENTIFIED AS MUTAGEN IN VITRO Active FR3059429B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1661745A FR3059429B1 (en) 2016-11-30 2016-11-30 PROCESS FOR IMPUTING A NON-NEGATIVE RESPONSE OBTAINED IN A REVERSE MUTATION TEST ON BACTERIA, CARRIED OUT FROM A PHARMACEUTICAL, COSMETIC OR NUTRITIONAL PREPARATION, AT LEAST ONE CONSTITUENT IDENTIFIED AS MUTAGEN IN VITRO

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1661745 2016-11-30
FR1661745A FR3059429B1 (en) 2016-11-30 2016-11-30 PROCESS FOR IMPUTING A NON-NEGATIVE RESPONSE OBTAINED IN A REVERSE MUTATION TEST ON BACTERIA, CARRIED OUT FROM A PHARMACEUTICAL, COSMETIC OR NUTRITIONAL PREPARATION, AT LEAST ONE CONSTITUENT IDENTIFIED AS MUTAGEN IN VITRO

Publications (2)

Publication Number Publication Date
FR3059429A1 FR3059429A1 (en) 2018-06-01
FR3059429B1 true FR3059429B1 (en) 2020-09-04

Family

ID=58054268

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1661745A Active FR3059429B1 (en) 2016-11-30 2016-11-30 PROCESS FOR IMPUTING A NON-NEGATIVE RESPONSE OBTAINED IN A REVERSE MUTATION TEST ON BACTERIA, CARRIED OUT FROM A PHARMACEUTICAL, COSMETIC OR NUTRITIONAL PREPARATION, AT LEAST ONE CONSTITUENT IDENTIFIED AS MUTAGEN IN VITRO

Country Status (1)

Country Link
FR (1) FR3059429B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022071238A1 (en) * 2020-09-29 2022-04-07
FR3133860B1 (en) * 2022-03-23 2025-01-10 Genevolution Method for detecting the mutagenic nature of chemical compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004024518D1 (en) * 2003-04-26 2010-01-21 Merck & Co Inc FORWARD MUTATION TEST BASED ON 5-FLUORURA CURRENT RESISTANCE
EP2258391A1 (en) * 2009-06-05 2010-12-08 Stallergenes S.A. Reduction of in vitro genotoxicity of pollen extracts by removal of flavonoids
FR2950532B1 (en) * 2009-09-30 2012-06-22 Natura Cosmeticos Sa PROCESS FOR THE PREPARATION OF AN EXTRACT OF PLANTS OF THE GENUS SCLEROLOBIUM, COSMETIC AND PHARMACEUTICAL COMPOSITION COMPRISING THIS EXTRACT AND THE USE OF SAID EXTRACT

Also Published As

Publication number Publication date
FR3059429A1 (en) 2018-06-01

Similar Documents

Publication Publication Date Title
EP3622080C0 (en) IMPROVED PROCESSES FOR THE PRODUCTION OF ISOBUTENE FROM 3-METHYLCROTONIC ACID
BR112015026766A2 (en) hydroxycarboxylic acid processing for polymers
EP4524255A3 (en) Methods and compositions for nucleic acid analysis
WO2016196315A3 (en) Cell culture methods and systems
WO2016185211A8 (en) Process for the biological production of methacrylic acid and derivatives thereof
FR3028866B1 (en) METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR DETERMINING THE GROWTH OF MICROORGANISMS
EP3420004A4 (en) COPOLYMER COMPOSITIONS OF OXYGEN AND CAROTENOIDS DERIVED FROM MICROORGANISMS OR PLANTS, METHODS OF IDENTIFYING, QUANTIFYING AND PRODUCING THE COPOLYMERS, AND USES THEREOF
EP3766521A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING AN AMINO ACID DERIVATIVE MARKED WITH 211AT, AND PROCESS FOR PRODUCING THE SAID PHARMACEUTICAL COMPOSITION
FR2992849B1 (en) BLADE FOR PREPARING AN ENDOTHELIAL GRAFT AND PROCESS FOR PREPARING THE SAME
FR3059429B1 (en) PROCESS FOR IMPUTING A NON-NEGATIVE RESPONSE OBTAINED IN A REVERSE MUTATION TEST ON BACTERIA, CARRIED OUT FROM A PHARMACEUTICAL, COSMETIC OR NUTRITIONAL PREPARATION, AT LEAST ONE CONSTITUENT IDENTIFIED AS MUTAGEN IN VITRO
WO2018033227A8 (en) Anti-ageing pharmaceutical preparation
EP3528820A4 (en) NOVEL PEGYLATED APELINE LIPOSOMAL FORMULATIONS FOR THE TREATMENT OF CARDIOVASCULAR SYSTEM-RELATED DISEASES
EP3519567A4 (en) MODIFIED MICROORGANISMS FOR THE PRODUCTION OF BASIC CHEMICALS AND CELL BIOMASS
EP3851550A4 (en) FERRITIC STAINLESS STEEL SHEET, PROCESS FOR THE PRODUCTION AND AL-PLATED STAINLESS STEEL SHEET
FR3046541B1 (en) ACTIVE PRINCIPLE OBTAINED FROM OPHIOPOGON JAPONICUS FOR THE TREATMENT OF ATOPIC DERMATITIS
EP3488926A4 (en) CATALYST, PROCESS FOR PRODUCTION OF ACRYLIC ACID, AND PROCESS FOR PRODUCTION OF CATALYST
EP4242305A3 (en) Process for immobilization of a lipase
MA39445A1 (en) Selection, production and feeding of whole algae as a dietary supplement for livestock and bison to produce high omega 3's for human health
PL410898A1 (en) Method for obtaining lactic acid esters and lactate lactic acid esters in the reaction of aliphatic polyester alcoholysis
EP3866291A4 (en) DC HOUSEHOLD POWER SYSTEM AND SYSTEM-BASED HOUSEHOLD WIRING PROCESS
EP3960359A4 (en) MACHINING APPARATUS, MACHINING PROCESS AND MACHINING SYSTEM
FR3016637B1 (en) GLYCOSAMINOGLYCANE IN VIVO PRODUCTION PROCESS
EP2666850A4 (en) BIOLOGICAL CULTURE OF A STRAIN OF THE SPECIES PSEUDOMONAS GRAMINIS, USE OF SAID CROP AS ANTAGONIST FOR BIOLOGICAL CONTROL OF PATHOGENIC BACTERIA AND METHOD FOR TREATING FRUITS COMPRISING A STAGE OF APPLICATION, ON FRUITS, OF A PREPARATION CONTAINING THE BIOLOGICAL CULTURE
PL418557A1 (en) 4'-O-β-D-glucopyranosyl-4,2'-dihydroxy-3'-[3"-methylbutyl]-6'-methoxy-α,β-dihydrochalcone and method for obtaining 4'-O-β-D-glucopyranosyl-4,2'-dihydroxy-3'-[3"-methylbutyl]-6'-methoxy-α,β-dihydrochalcone
BR112018074714A2 (en) process for forming iron-fortified nutritional products

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

EXTE Extension to a french territory

Extension state: PF

PLSC Publication of the preliminary search report

Effective date: 20180601

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10